Research programme: immuno-oncology therapies - FLX Bio

Drug Profile

Research programme: immuno-oncology therapies - FLX Bio

Alternative Names: CCR4 inhibitors - FLX Bio; GCN2 inhibitors - FLX Bio; GCN2 program - FLX Bio; MDSC inhibitors - FLX Bio; Myeloid-derived suppressor cell inhibitors - FLX Bio; Regulatory T-cell inhibitors - FLX Bio; USP7 inhibitors - FLX Bio

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FLX Bio
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action CCR4 receptor antagonists; EIF2AK4 protein inhibitors; Regulatory T lymphocyte inhibitors; USP7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Apr 2018 Updated pharmacodynamic data from preclinical studies in Cancer released by FLX Bio
  • 17 Apr 2017 Pharmacodynamic data from preclinical studies in Cancer presented at the 108th Annual meeting of the American Association of Cancer Research (AACR-2017)
  • 01 Jan 2017 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top